TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation
Oncology Research · 2025 · 33 (1) · 161-169
DOI: 10.32604/or.2024.048054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Xiuwang Wei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530000, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Forkhead Box Protein O3, Forkhead Box Protein O1, Cell Proliferation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Transmembrane emp24 trafficking protein 3 (TMED3) is associated with the development of several tumors; however, whether TMED3 regulates the progression of prostate cancer remains unclear. Materials and Methods: Short hairpin RNA was performed to repress TMED3 in prostate cancer cells (DU145 cells) and in a prostate cancer mice model to determine its function in prostate cancer in vitro and in vivo.
Results
In the present study, we found that TMED3 was highly expressed in prostate cancer cells. In vitro, shTMED3 treatment suppressed the proliferation, invasion, and migration and promoted the apoptosis of DU145 cells. Additionally, the Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis showed a strong correlation between TMED3 and forkhead box O transcription factor (FOXO) pathway. Furthermore, TMED3 inhibition efficiently decreased FOXO1a and FOXO3a phosphorylation. In vivo, TMED3 downregulation suppressed the apoptosis, growth, and metastasis of prostate cancer cells via FOXO1a and FOXO3a.
Conclusion
The present findings show that TMED3 participates in the regulation of prostate cancer progression via FOXO1a and FOXO3a phosphorylation, thereby revealing a novel mechanism underlying prostate cancer development and suggesting that TMED3 inhibition may serve as a novel strategy for prostate cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530000, China.
- Department of Rehabilitation, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530000, China.
Zitieren
APA
Wei, X., Liang, J., Huang, H., Yang, D., Wang, X., Wang, X., Chen, C., Li, K., Pang, T., Hu, B., & Wu, F. (2025). TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation. Oncology Research, 33(1), 161-169. https://doi.org/10.32604/or.2024.048054
Vancouver
Wei X, Liang J, Huang H, Yang D, Wang X, Wang X, et al. TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation. Oncology Research. 2025;33(1):161-169. doi:10.32604/or.2024.048054
BibTeX
@article{Wei2025,
author = {Wei, Xiuwang and Liang, Jianbo and Huang, Huanwen and Yang, Daming and Wang, Xinxin and Wang, Xiujia and Chen, Changsheng and Li, Kaiqiang and Pang, Taisen and Hu, Bin and Wu, Fengning},
title = {TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation},
journal = {Oncology Research},
year = {2025},
volume = {33},
number = {1},
pages = {161--169},
doi = {10.32604/or.2024.048054}
}
EUVIMED